Melatonin and mitochondrial dysfunction in the central nervous system

Hormones and Behavior

Volumn 63, Issue 2, 2013, Pages 322-330

  Cardinali, Daniel P ^a   Pagano, Eleonora S ^a   Scacchi Bernasconi, Pablo A ^a   Reynoso, Roxana ^a   Scacchi, Pablo ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

Author keywords

Aging; Alzheimer's disease; Free radicals; Huntington's disease; Melatonin; Melatonin analogs; Mitochondria; Oxidative stress; Parkinson's disease

Indexed keywords

AGOMELATINE; FREE RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; LY 156735; MELATONIN; MELATONIN DERIVATIVE; NITRIC OXIDE; PLACEBO; RAMELTEON; REACTIVE OXYGEN METABOLITE; TASIMELTEON; TIK 301; TK 301; UNCLASSIFIED DRUG; VES 162;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROWSINESS; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; ELECTRON TRANSPORT; ENZYME ACTIVITY; HORMONE ACTION; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MUSCULAR DYSTROPHY; NEUROPATHOLOGY; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; TARDIVE DYSKINESIA; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; HUNTINGTON DISEASE; MELATONIN; MITOCHONDRIA; PARKINSON DISEASE;

EID: 84872843163     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2012.02.020     Document Type: Review

References (126)

1. Absi E., Ayala A., Machado A., Parrado J. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J. Pineal Res. 2000, 29:40-47.
2. Acuña Castroviejo D., López L.C., Escames G., López A., García J.A., Reiter R.J. Melatonin-mitochondria interplay in health and disease. Curr. Top. Med. Chem. 2011, 11:221-240.
3. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.X., Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14447-14452.
4. Andrabi S.A., Sayeed I., Siemen D., Wolf G., Horn T.F. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. 2004, 18:869-871.
5. Antolin I., Rodríguez C., Sainz R.M., Mayo J.C., Uria H., Kotler M.L., Rodríguez-Colunga M.J., Tolivia D., Menéndez-Pelaez A. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J. 1996, 10:882-890.
6. Barratt G.F., Nadakavukaren M.J., Frehn J.L. Effect of melatonin implants on gonadal weights and pineal gland fine structure of the golden hamster. Tissue Cell 1977, 9:335-345.
7. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S189-S194.
8. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J. Pineal Res. 2006, 40:1-9.
9. Bobba A., Petragallo V.A., Marra E., Atlante A. Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int. J. Alzheimers Dis. 2010, (Article ID 621870). 10.4061/2010/621870.
10. Bonilla E., Tanji K., Hirano M., Vu T.H., DiMauro S., Schon E.A. Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta 1999, 1410:171-182.
11. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
12. Cardinali D.P., Lynch H.J., Wurtman R.J. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972, 91:1213-1218.
13. Cardinali D.P., Furio A.M., Brusco L.I. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr. Neuropharmacol. 2010, 8:218-227.
14. Cardinali, D. P., Srinivasan, V., Brzezinski, A., Brown, G. M., in press. Melatonin and its analogs in insomnia and depression. J. Pineal Res., Doi:. doi:10.1111/j.1600-079X.2011.00962.x.
15. Carrillo-Vico A., Reiter R.J., Lardone P.J., Herrera J.L., Fernandez-Montesinos R., Guerrero J.M., Pozo D. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs 2006, 7:423-431.
16. Ceraulo L., Ferrugia M., Tesoriere L., Segreto S., Livrea M.A., Turco L.V. Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J. Pineal Res. 1999, 26:108-112.
17. Chahbouni M., Escames G., Venegas C., Sevilla B., García J.A., López L.C., Muñoz-Hoyos A., Molina-Carballo A., Acuña-Castroviejo D. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J. Pineal Res. 2010, 48:282-289.
18. Chang H.M., Wu U.I., Lan C.T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J. Pineal Res. 2009, 47:211-220.
19. Chang C.F., Huang H.J., Lee H.C., Hung K.C., Wu R.T., Lin A.M. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and alpha-synuclein aggregation. J. Pineal Res. 2011, [Epub ahead of print]. 10.1111/j.1600-079X.2011.00945.x.
20. Chen C.M. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med. J. 2011, 34:135-152.
21. Chen J.X., Yan S.S. Role of mitochondrial amyloid-beta in Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S569-S578.
22. Claustrat B., Brun J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9:11-24.
23. Cuzzocrea S., Costantino G., Caputi A.P. Protective effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in a non-septic shock model induced by zymosan in the rat. J. Pineal Res. 1998, 25:78-85.
24. Decker J.F., Quay W.B. Stimulatory effects of melatonin on ependymal epithelium of choroid plexuses in golden hamsters. J. Neural Transm. 1982, 55:53-67.
25. DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annu. Rev. Neurosci. 2008, 31:91-123.
26. Dong W., Huang F., Fan W., Cheng S., Chen Y., Zhang W., Shi H., He H. Differential effects of melatonin on amyloid-beta peptide 25-35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture. J. Pineal Res. 2010, 48:117-125.
27. Dragicevic N., Copes N., O'Neal-Moffitt G., Jin J., Buzzeo R., Mamcarz M., Tan J., Cao C., Olcese J.M., Arendash G.W., Bradshaw P.C. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 2011, 51:75-86.
28. Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010, 62:343-380.
29. Esposito E., Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 2010, 8:228-242.
30. Facciola G., Hidestrand M., von Bahr C., Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 2001, 56:881-888.
31. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., Zhang J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res. 2004, 37:129-136.
32. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 2011, 51:1-16.
33. Galindo M.F., Ikuta I., Zhu X., Casadesus G., Jordan J. Mitochondrial biology in Alzheimer's disease pathogenesis. J. Neurochem. 2010, 114:933-945.
34. Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., Cummings J.L., de Leon M., Feldman H., Ganguli M., Hampel H., Scheltens P., Tierney M.C., Whitehouse P., Winblad B. Mild cognitive impairment. Lancet 2006, 367:1262-1270.
35. Genova M.L., Pich M.M., Bernacchia A., Bianchi C., Biondi A., Bovina C., Falasca A.I., Formiggini G., Castelli G.P., Lenaz G. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann. N. Y. Acad. Sci. 2004, 1011:86-100.
36. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802:122-134.
37. Gleichmann M., Mattson M.P. Neuronal calcium homeostasis and dysregulation. Antioxid. Redox Signal. 2011, 14:1261-1273.
38. Guarente L. Mitochondria-a nexus for aging, calorie restriction, and sirtuins?. Cell 2008, 132:171-176.
39. Gutierrez-Cuesta J., Tajes M., Jimenez A., Coto-Montes A., Camins A., Pallas M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J. Pineal Res. 2008, 45:497-505.
40. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27:119-130.
41. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009, 35:183-192.
42. Hardeland R., Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab. (Lond.) 2005, 2:22.
43. Hardeland R., Coto-Montes A., Poeggeler B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol. Int. 2003, 20:921-962.
44. Hardeland R., Tan D.X., Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47:109-116.
45. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93:350-384.
46. Hartter S., Ursing C., Morita S., Tybring G., von Bahr C., Christensen M., Rojdmark S., Bertilsson L. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin. Pharmacol. Ther. 2001, 70:10-16.
47. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6739-6744.
48. Horton T.M., Graham B.H., Corral-Debrinski M., Shoffner J.M., Kaufman A.E., Beal M.F., Wallace D.C. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 1995, 45:1879-1883.
49. Hung C.H., Ho Y.S., Chang R.C. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease. Ageing Res. Rev. 2010, 9:447-456.
50. Jang M.H., Jung S.B., Lee M.H., Kim C.J., Oh Y.T., Kang I., Kim J., Kim E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett. 2005, 380:26-31.
51. Jimenez-Ortega V., Cano P., Cardinali D.P., Esquifino A.I. 24-Hour variation in gene expression of redox pathway enzymes in rat hypothalamus: effect of melatonin treatment. Redox Rep. 2009, 14:132-138.
52. Jou M.J., Peng T.I., Reiter R.J., Jou S.B., Wu H.Y., Wen S.T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res. 2004, 37:55-70.
53. Jou M.J., Peng T.I., Yu P.Z., Jou S.B., Reiter R.J., Chen J.Y., Wu H.Y., Chen C.C., Hsu L.F. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J. Pineal Res. 2007, 43:389-403.
54. Karbownik M., Tan D., Manchester L.C., Reiter R.J. Renal toxicity of the carcinogen delta-aminolevulinic acid: antioxidant effects of melatonin. Cancer Lett. 2000, 161:1-7.
55. 2 receptor agonist. Neuropharmacology 2005, 48:301-310.
56. Klongpanichapak S., Phansuwan-Pujito P., Ebadi M., Govitrapong P. Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells. Neurosci. Lett. 2008, 436:309-313.
57. Leger D., Laudon M., Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am. J. Med. 2004, 116:91-95.
58. Lemasters J.J., Theruvath T.P., Zhong Z., Nieminen A.L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta 2009, 1787:1395-1401.
59. Lenaz G., Genova M.L. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid. Redox Signal. 2010, 12:961-1008.
60. Lin A.M., Fang S.F., Chao P.L., Yang C.H. Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein. J. Pineal Res. 2007, 43:163-171.
61. Liochev S.I., Fridovich I. Mechanism of the peroxidase activity of Cu, Zn superoxide dismutase. Free Radic. Biol. Med. 2010, 48:1565-1569.
62. Lombard D.B., Alt F.W., Cheng H.L., Bunkenborg J., Streeper R.S., Mostoslavsky R., Kim J., Yancopoulos G., Valenzuela D., Murphy A., Yang Y., Chen Y., Hirschey M.D., Bronson R.T., Haigis M., Guarente L.P., Farese R.V., Weissman S., Verdin E., Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 2007, 27:8807-8814.
63. López A., García J.A., Escames G., Venegas C., Ortiz F., López L.C., Acuña-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009, 46:188-198.
64. Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N., Chalmers R.M., Oldfors A., Rautakorpi I., Peltonen L., Majamaa K., Somer H., Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004, 364:875-882.
65. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010, 20(Suppl. 2):S609-S631.
66. Mander P., Brown G.C. Nitric oxide, hypoxia and brain inflammation. Biochem. Soc. Trans. 2004, 32:1068-1069.
67. Martin M., Macias M., Escames G., Leon J., Acuña-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J. 2000, 14:1677-1679.
68. Martin M., Macias M., Escames G., Reiter R.J., Agapito M.T., Ortiz G.G., Acuña-Castroviejo D. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J. Pineal Res. 2000, 28:242-248.
69. Massaad C.A., Pautler R.G., Klann E. Mitochondrial superoxide: a key player in Alzheimer's disease. Aging (Albany NY) 2009, 1:758-761.
70. Mathes A., Kubuls D., Waibel L., Weiler J., Heymann P., Wolf B., Rensing H. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit. Care Med. 2008, 36:2863-2870.
71. Matsubara E., Bryant-Thomas T., Pacheco Q.J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
72. Messner M., Hardeland R., Rodenbeck A., Huether G. Tissue retention and subcellular distribution of continuously infused melatonin in rats under near physiological conditions. J. Pineal Res. 1998, 25:251-259.
73. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003, 306:954-964.
74. 2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci. Ther. 2009, 15:32-51.
75. Mulchahey J.J., Goldwater D.R., Zemlan F.P. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci. 2004, 75:1843-1856.
76. Muller W.E., Eckert A., Kurz C., Eckert G.P., Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol. Neurobiol. 2010, 41:159-171.
77. Navarro A., Boveris A. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front. Aging Neurosci 2010, 2. (Sep 1; pii: 3).
78. Olcese J.M., Cao C., Mori T., Mamcarz M.B., Maxwell A., Runfeldt M.J., Wang L., Zhang C., Lin X., Zhang G., Arendash G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009, 47:82-96.
79. Oliveira J.M. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J. Neurochem. 2010, 114:1-12.
80. Oliveira J.M. Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Curr. Drug Targets 2011, 12:762-773.
81. Ono K., Mochizuki H., Ikeda T., Nihira T., Takasaki J.I., Teplow D.B., Yamada M. Effect of melatonin on alpha-synuclein self-assembly and cytotoxicity. Neurobiol. Aging 2011, [Epub ahead of print]. 10.1016/j.neurobiolaging.2011.10.015.
82. Pablos M.I., Reiter R.J., Ortiz G.G., Guerrero J.M., Agapito M.T., Chuang J.I., Sewerynek E. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem. Int. 1998, 32:69-75.
83. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggiero F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
84. Petrosillo G., Fattoretti P., Matera M., Ruggiero F.M., Bertoni-Freddari C., Paradies G. Melatonin prevents age-related mitochondrial dysfunction in rat brain via cardiolipin protection. Rejuvenation Res. 2008, 11:935-943.
85. Pivovarova N.B., Andrews S.B. Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J. 2010, 277:3622-3636.
86. Quinn J., Kulhanek D., Nowlin J., Jones R., Pratico D., Rokach J., Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 2005, 1037:209-213.
87. Raha S., Robinson B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 2000, 25:502-508.
88. Rajaratnam S.M., Polymeropoulos M.H., Fisher D.M., Roth T., Scott C., Birznieks G., Klerman E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009, 373:482-491.
89. Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010, 20(Suppl. 2):S499-S512.
90. Reiter R.J., Paredes S.D., Manchester L.C., Tan D.X. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 2009, 44:175-200.
91. Reyes Toso C.F., Rebagliati I.R., Ricci C., Linares L.M., Albornoz L.E., Cardinali D.P., Zaninovich A.A. Effect of melatonin treatment on oxygen consumption by rat liver mitochondria. Amino Acids 2006, 31:299-302.
92. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 2009, 34:1021-1029.
93. Rodriguez C., Mayo J.C., Sainz R.M., Antolin I., Herrera F., Martin V., Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 2004, 36:1-9.
94. Rollins B., Martin M.V., Sequeira P.A., Moon E.A., Morgan L.Z., Watson S.J., Schatzberg A., Akil H., Myers R.M., Jones E.G., Wallace D.C., Bunney W.E., Vawter M.P. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One 2009, 4:e4913.
95. Sae-Ung K., Ueda K., Govitrapong P., Phansuwan-Pujito P. Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J. Pineal Res. 2012, 52:128-137.
96. Sainz R.M., Mayo J.C., Rodriguez C., Tan D.X., Lopez-Burillo S., Reiter R.J. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol. Life Sci. 2003, 60:1407-1426.
97. Santos R.X., Correia S.C., Wang X., Perry G., Smith M.A., Moreira P.I., Zhu X. Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int. J. Clin. Exp. Pathol. 2010, 3:570-581.
98. Santucci R., Sinibaldi F., Patriarca A., Santucci D., Fiorucci L. Misfolded proteins and neurodegeneration: role of non-native cytochrome c in cell death. Expert Rev. Proteomics 2010, 7:507-517.
99. Schapira A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta 1999, 1410:159-170.
100. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004, 318:215-224.
101. Schon E.A., DiMauro S., Hirano M., Gilkerson R.W. Therapeutic prospects for mitochondrial disease. Trends Mol. Med. 2010, 16:268-276.
102. Srinivasan V., Cardinali D.P., Srinivasan U.S., Kaur C., Brown G.M., Spence D.W., Hardeland R., Pandi-Perumal S.R. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 2011, 4:297-317.
103. Srinivasan V., Kaur C., Pandi-Perumal S.R., Brown G.M., Cardinali D.P. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int. J. Alzheimers Dis. 2011, 2011:1-15. 10.4061/2011/741974.
104. Srinivasan V., Spence D.W., Pandi-Perumal S.R., Brown G.M., Cardinali D.P. Melatonin in mitochondrial dysfunction and related disorders. Int. J. Alzheimers Dis. 2011, 2011:1-15. 10.4061/2011/326320.
105. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
106. Tajes M., Gutierrez-Cuesta J., Ortuno-Sahagun D., Camins A., Pallas M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J. Pineal Res. 2009, 47:228-237.
107. Tan D., Reiter R.J., Chen L.D., Poeggeler B., Manchester L.C., Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 1994, 15:215-218.
108. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
109. 1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J. Neurosci. Res. 2009, 87:3002-3010.
110. Terzioglu M., Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 2008, 275:1384-1391.
111. Toman J., Fiskum G. Influence of aging on membrane permeability transition in brain mitochondria. J. Bioenerg. Biomembr. 2011, 43:3-10.
112. Trancikova, A., Tsika, E., Moore, D. J., in press. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid. Redox. Signal.
113. Tunez I., Montilla P., Del Carmen M.M., Feijoo M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res. 2004, 37:252-256.
114. Turek F.W., Gillette M.U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004, 5:523-532.
115. Urata Y., Honma S., Goto S., Todoroki S., Iida T., Cho S., Honma K., Kondo T. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med. 1999, 27:838-847.
116. Vachharajani N.N., Yeleswaram K., Boulton D.W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J. Pharm. Sci. 2003, 92:760-772.
117. Venegas C., Garcia J.A., Escames G., Ortiz F., Lopez A., Doerrier C., Garcia-Corzo L., Lopez L.C., Reiter R.J., Acuña-Castroviejo D. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res. 2012, 52:217-227.
118. Voordouw B.C., Euser R., Verdonk R.E., Alberda B.T., de Jong F.H., Drogendijk A.C., Fauser B.C., Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J. Clin. Endocrinol. Metab. 1992, 74:108-117.
119. Waldhauser F., Waldhauser M., Lieberman H.R., Deng M.H., Lynch H.J., Wurtman R.J. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984, 39:307-313.
120. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19318-19323.
121. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
122. Weishaupt J.H., Bartels C., Polking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., Huther G., Schneider A., Bach A., Siren A.L., Hardeland R., Bahr M., Nave K.A., Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006, 41:313-323.
123. Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A.N., Britton T.C., Crowe C., Dijk D.J., Espie C.A., Gringras P., Hajak G., Idzikowski C., Krystal A.D., Nash J.R., Selsick H., Sharpley A.L., Wade A.G. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J. Psychopharmacol. 2010, 24:1577-1601.
124. Xu M., Ashraf M. Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential. J. Mol. Cell. Cardiol. 2002, 34:75-79.
125. Zhdanova I.V., Wurtman R.J., Regan M.M., Taylor J.A., Shi J.P., Leclair O.U. Melatonin treatment for age-related insomnia. J. Clin. Endocrinol. Metab. 2001, 86:4727-4730.
126. 1-42. J. Pineal Res. 2008, 45:157-165.